FDA Inspection 1316122 — Hanlim Pharm Co. Ltd.
The FDA completed an inspection of Hanlim Pharm Co. Ltd. on Apr 10, 2026 in Yongin. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Apr 10, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Yongin (Korea (the Republic of))
Additional Details
Bioanalytical BA/BE